Peter Dudek

Scientist turned investor. Managing Partner at MRL Ventures @Merck. Opinions are my own etc

[Peter Dudek @dud3k]

@LifeSciVC Blast from the past! The Kevins were fun to work with as was hanging out with the Atlas team at Grosvenor Square.

[Peter Dudek @dud3k]

@DueDoctor @BowTiedBiotech That’s because those numbers are YOY growth, not total sales. For 2023, Keytruda was $25Bn, Ozempic was $13.9Bn and Mounjaro was $5Bn.

[Peter Dudek @dud3k]

@pkedrosky You can always add a squat goal (1.5x your weight) and deadlift goal (2x your weight), to make it interesting. 😉

[Peter Dudek @dud3k]

@AppleHelix This might’ve been the case for VCs with multi-stage strategies, but there are (and were) many (including ourselves) that did not change our early stage investment cadence. Many announced (and not yet announced) preclinical financings in the past 6 months were highly competitive.

[Peter Dudek @dud3k]

@eperlste @JasonSynaptic Ethan has a point. There are loads of postdocs available in biopharma w/cultures that encourage publishing if that’s important to u. Also u get to play with toys rarely accessible in academic environments due to cost. Here’s a link to Merck’s program: https://t.co/oFBf9OKH2x

[Peter Dudek @dud3k]

@LifeSciVC Some will be limited with what they can do by their LPAs, and only larger funds are likely to be able to tap into mgmt fees to get around that. Some are even directly entangled with SVB themselves. I would be surprised if all that want to step up, can.

[Peter Dudek @dud3k]

@dougall @gdibner Except they weren’t offering the highest rates, which is what caused the deposit decay in the first place. @gdibner is spot on.

[Peter Dudek @dud3k]

@LifeSciVC One of my favorite events! Not least because we invested in a past presenter who had founded a newco. Thanks for (re)launching it!

[Peter Dudek @dud3k]

@jrdorkin @gdibner It takes two to tango.

[Peter Dudek @dud3k]

@VishalGulati_ Call me when we’ve built one with enough qubits to do an atomic level molecular dynamics simulation of the entire energy landscape of a protein in solution ;)

[Peter Dudek @dud3k]

@WorkMJ This is not an issue limited to deeptech. $FSTX (originally venture-backed biotech in Vienna/Cambridge,UK) is an active case in point.

[Peter Dudek @dud3k]

@michaelzlin @Nature @NaturePortfolio Invented in the US, developed in China. Those two things can both be true.

[Peter Dudek @dud3k]

Great chatting with you @StephenPHansen. We’ve had our heads down for a while so it was nice to come out of the woodwork. 😉 https://t.co/J3ZBhFgT0r

[Peter Dudek @dud3k]

@michael_gilman There’s always this side hustle 😜 https://t.co/oHCVnAwgki

[David E. Weekly @dweekly]

I sued a spammer!

Did you know you have a right to sue folks that send you unsolicited text messages or calls?

I received a check for $1,200 today as settlement of a TCPA suit against a party that sent me an unsolicited text message.

[Peter Dudek @dud3k]

Having come out of yeast genetics labs during my PhD/postdoc days, it’s been hard not to be impressed by the promise of Lifemine’s platform. Congrats to @glostaman and team on the transformational partnership and financing: https://t.co/izSFLx1PvT

[Peter Dudek @dud3k]

@LifeSciVC Did I just read new soundtrack to a D&D campaign? Take my wallet??

[Peter Dudek @dud3k]

Oh dear.

[Peter Dudek @dud3k]

@cbrenn22 🤣

[Peter Dudek @dud3k]

@simonbayly You can lease them 😉

[Peter Dudek @dud3k]

@sciencescanner Why not both? I agree BETTER trumps FASTER on average and in a resource-constrained envmt this should be the prefrd path, but BETTER can be constrained by available resources too. Enabling BETTER with more resources can lead to FASTER without compromise.